NASDAQ: MNKDMannkind Corp Stock
$3.52-0.03 (-0.85%)
Updated May 8, 2026
MNKD Price
$3.52
Fair Value Price
N/A
Market Cap
$1.09B
52 Week Low
$2.23
52 Week High
$6.51
P/E
-50.29x
P/B
-18.37x
P/S
2.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$360.78M
Earnings
-$23.91M
Gross Margin
75.6%
Operating Margin
3.12%
Profit Margin
-6.6%
Debt to Equity
-13.58
Operating Cash Flow
$19M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MNKD Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNKD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNKD
Ranked#309 of 458
Ranked#309 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.79 | A | |
| $48.16 | A | |
| $7.49 | A |
Be the first to know about important MNKD news, forecast changes, insider trades & much more!
MNKD News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNKD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNKD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNKD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MNKD's Earnings (EBIT) of $11.26M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MNKD due diligence checks available for Premium users.
Valuation
MNKD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-50.29x
Industry
16.15x
Market
23.09x
MNKD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-18.37x
Industry
4.99x
MNKD's financial health
Profit margin
Revenue
$90.2M
Net Income
-$16.6M
Profit Margin
-18.4%
MNKD's Earnings (EBIT) of $11.26M... subscribe to Premium to read more.
Interest Coverage Financials
MNKD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$744.4M
Liabilities
$803.6M
Debt to equity
-13.58
MNKD's short-term assets ($251.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNKD's long-term liabilities ($669.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNKD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNKD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
$18.7M
Financing
-$35.4M
MNKD's operating cash flow ($19.27M)... subscribe to Premium to read more.
Debt Coverage Financials
MNKD vs Biotech Stocks
Mannkind Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.